Collaboration unveiled to develop diagnostic tests
Abingdon Health, a manufacturer of medical tests, has signed a Testing Services Framework Agreement with DeepVerge to make lateral flow tests (LFTs) for DeepVerge’s Modern Water and Life Science divisions.
DeepVerge is an environmental and life science group, which develops and applies AI and IoT technology for the analysis and identification of bacteria, viruses and toxins.
Its agreement with York-based Abingdon follows on from a strategic collaboration announcement made on 29 March 2022.
The companies will work on the development of LFT devices for DeepVerge’s Modern Water division to detect dangerous pathogens and chemicals in household drinking and wastewater, as well as Environmental LFT tests covering acrylamide, microcystins, and algae.
They will also collaborate on the development of new lateral flow tests to be added to DeepVerge’s life science home test portfolio, including hormone analysis related to menopause and associated skin changes and other health markers.
DeepVerge will fund the development cost of the projects being undertaken and Abingdon will be exclusive manufacturer of the products developed and subsequently transferred into manufacturing.
Gerard Brandon, CEO of DeepVerge, said: “Leveraging the skillsets between DeepVerge and Abingdon to produce a range of new LFT tests, in such a short period of time, for the environmental and human health sectors is an example of the creative and adaptable skillsets that exist within the UK diagnostics industry.
“DeepVerge Group are looking forward to add these innovative new LFT units, produced entirely in the UK, to our 60 plus country distribution channels in early 2023.”
Chris Yates, CEO of Abingdon Health, added: “We are pleased to have signed this commercial agreement with DeepVerge.
“This strategic partnership will allow both companies to build a long-term collaboration to enable DeepVerge to leverage Abingdon’s lateral flow development and manufacturing engine to launch a range of innovate tests into its core markets.
“This agreement underlines Abingdon’s reputation as a knowledge leader and expert in the rapidly growing lateral flow testing market.”
